Form 8-K - Current report:
SEC Accession No. 0001193125-25-085773
Filing Date
2025-04-18
Accepted
2025-04-18 16:16:40
Documents
14
Period of Report
2025-04-17
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 8-K d792758d8k.htm   iXBRL 8-K 25638
  Complete submission text file 0001193125-25-085773.txt   183529

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tpst-20250417.xsd EX-101.SCH 3883
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20250417_def.xml EX-101.DEF 13698
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20250417_lab.xml EX-101.LAB 22682
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20250417_pre.xml EX-101.PRE 14666
17 EXTRACTED XBRL INSTANCE DOCUMENT d792758d8k_htm.xml XML 5520
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 25850586
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)